Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal.~2. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential, the participant or the participant's non-pregnant female partner must be using a highly effective contraceptive method~3. Body Mass Index (BMI) ≤ 35.0 kg/m2~4. Participant must have been diagnosed with essential hypertension for a minimum of 3 months prior to screening~5. At Screening, on a stable regimen of antihypertensive medications for at least 1 month prior to screening~6. Agree to conduct at home Blood Pressure (BP) and Heart Rate (HR) monitoring three times weekly and document the average of the triplicate measurements assessed on a day in the patient diary~Exclusion Criteria~1. Clinically-significant (CS) abnormalities in medical history, screening laboratory results, physical or physical examination that would render a participant unsuitable for inclusion~2. The use of the following at time of screening and during the course of the study:~   1. Other medications for the treatment of hypertension (e.g., clonidine, guanfacine, guanabenz, alpha-methyldopa, hydralazine, minoxidil, diazoxide, renin inhibitors)~  2. Medications that also may cause hyperkalemia (e.g., cyclosporine or tacrolimus, pentamidine, trimethoprim-sulfamethoxazole, all heparins)~  3. Oral or subcutaneous anticoagulants (e.g., warfarin, rivaroxaban, apixaban, heparin, lovenox)~  4. Organic nitrate preparations (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or pentaerythritol)~  5. Sildenafil, tadalafil, vardenafil~3. Unwilling to discontinue antihypertensive mediations during Wash Out (WO) and Treatment Period of study~4. Participant has a history of secondary hypertension~5. Unstable/underlying cardiovascular disease defined as:~   1. Any history of congestive heart failure (NYHA class II-IV)~  2. Any history of previous stroke, transient ischemic attack, unstable or stable angina pectoris, or myocardial infarction prior to screening~  3. a history or evidence of long QT syndrome~  4. Any CS active atrial or ventricular arrhythmias~  5. Any history of coronary bypass or percutaneous coronary intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching solution injected subcutaneously (SC) once weekly for up to 6 weeks and an additional loading dose on Day 3.
- ISIS 757456 80 mg (Type: EXPERIMENTAL): ISIS 757456 80 mg injected SC once weekly for up to 6 weeks and an additional loading dose of 80 mg on Day 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).